"Alzheimer, a complex disease is decrypted".
LIVESTREAM FROM AARHUS UNIVERSITY
The lecture is taught in English/Foredraget afholdes på engelsk.
Lecturer: professor of molecular biology Christian Haass, Ludwig-Maximilians University Munich, Germany
Entry fee: free
No other disease is threatening our society as much as Alzheimer's disease. Every three seconds someone on our planet is hit by Alzheimer's disease and by 2050 we expect more than 131 million Alzheimer's patients worldwide!
Thus, we urgently need treatment to prevent a collapse of our ageing society. The only way to reach this ambitious goal is a detailed understanding of the mechanisms, which destroy our memory.
In all Alzheimer's brains, clumps of poisonous proteins, so called plaques and tangles, are deposited and kill our nervous cells.
In many years the genesis of these plaques in our brains, was thought to occur solely under pathogenic circumstances and thus primarily during aging. However, Haass proved that the basic mechanism involved in the constant generation of the building blocks of plaques is active in all of us from birth, which may explain the enormous risk we all have of suffering from Alzheimer's disease at some point.
Christian Haass will demonstrate that based on the discoveries of these mechanisms, treatment strategies have been developed aiming to slow or even prevent Alzheimer's disease. Such approaches can indeed prevent the accumulation of plaques in human patients, but so far they fail to stop the memory loss.
Is this a disaster indicating that scientists have worked on the wrong mechanisms? Christian Haass does not think so, he will rather demonstrate that plaque deposition starts decades before clinicians observe any memory decline.
The deposits in our brains slowly begin their deadly job by killing neurons early on and by the time memory loss becomes apparent, the brain is irrevocably damaged with the consequence that any treatment comes too late.
Thus, we do not only need efficacious and safe treatment strategies, but we must develop novel technologies to identify patients, which are at risk to develop Alzheimer's disease, at a time when no memory loss is observed.